| 000 | 01737 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513220044.0 | ||
| 264 | 0 | _c20000921 | |
| 008 | 200009s 0 0 eng d | ||
| 022 | _a1040-0605 | ||
| 024 | 7 |
_a10.1152/ajplung.2000.279.3.L496 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchütte, H | |
| 245 | 0 | 0 |
_aThe PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. _h[electronic resource] |
| 260 |
_bAmerican journal of physiology. Lung cellular and molecular physiology _cSep 2000 |
||
| 300 |
_aL496-502 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aCapillary Permeability _xdrug effects |
| 650 | 0 | 4 | _aCompliance |
| 650 | 0 | 4 |
_aCyclic GMP _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aIschemia _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNitric Oxide _xphysiology |
| 650 | 0 | 4 |
_aOrgan Size _xdrug effects |
| 650 | 0 | 4 |
_aPhosphodiesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPulmonary Artery _xphysiopathology |
| 650 | 0 | 4 |
_aPulmonary Circulation _xdrug effects |
| 650 | 0 | 4 |
_aPurinones _xpharmacology |
| 650 | 0 | 4 | _aRabbits |
| 650 | 0 | 4 |
_aReperfusion Injury _xmetabolism |
| 700 | 1 | _aWitzenrath, M | |
| 700 | 1 | _aMayer, K | |
| 700 | 1 | _aWeissmann, N | |
| 700 | 1 | _aSchell, A | |
| 700 | 1 | _aRosseau, S | |
| 700 | 1 | _aSeeger, W | |
| 700 | 1 | _aGrimminger, F | |
| 773 | 0 |
_tAmerican journal of physiology. Lung cellular and molecular physiology _gvol. 279 _gno. 3 _gp. L496-502 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1152/ajplung.2000.279.3.L496 _zAvailable from publisher's website |
| 999 |
_c10905166 _d10905166 |
||